158 related articles for article (PubMed ID: 27951496)
1. The timing of caffeic acid treatment with cisplatin determines sensitization or resistance of ovarian carcinoma cell lines.
Sirota R; Gibson D; Kohen R
Redox Biol; 2017 Apr; 11():170-175. PubMed ID: 27951496
[TBL] [Abstract][Full Text] [Related]
2. Caffeic acid phenethyl ester targets ubiquitin-specific protease 8 and synergizes with cisplatin in endometrioid ovarian carcinoma cells.
Colombo D; Gatti L; Sjöstrand L; Carenini N; Costantino M; Corna E; Arrighetti N; Zuccolo M; De Cesare M; Linder S; D'Arcy P; Perego P
Biochem Pharmacol; 2022 Mar; 197():114900. PubMed ID: 34995485
[TBL] [Abstract][Full Text] [Related]
3. Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol.
Perego P; Romanelli S; Carenini N; Magnani I; Leone R; Bonetti A; Paolicchi A; Zunino F
Ann Oncol; 1998 Apr; 9(4):423-30. PubMed ID: 9636834
[TBL] [Abstract][Full Text] [Related]
4. The role of the catecholic and the electrophilic moieties of caffeic acid in Nrf2/Keap1 pathway activation in ovarian carcinoma cell lines.
Sirota R; Gibson D; Kohen R
Redox Biol; 2015; 4():48-59. PubMed ID: 25498967
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
6. PGC1α promotes cisplatin resistance in human ovarian carcinoma cells through upregulation of mitochondrial biogenesis.
Shen L; Sun B; Sheng J; Yu S; Li Y; Xu H; Su J; Sun L
Int J Oncol; 2018 Jul; 53(1):404-416. PubMed ID: 29749474
[TBL] [Abstract][Full Text] [Related]
7. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells.
Jiao JW; Wen F
Oncol Rep; 2011 Mar; 25(3):781-8. PubMed ID: 21165580
[TBL] [Abstract][Full Text] [Related]
8. Messenger RNA expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin, taxol and cisplatin.
Masanek U; Stammler G; Volm M
Anticancer Drugs; 1997 Feb; 8(2):189-98. PubMed ID: 9073315
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of stepwise and pulse induced cisplatin-resistant ovarian cancer cell sublines].
Cheng G; Li Y; Tian F
Zhonghua Zhong Liu Za Zhi; 2001 Jul; 23(4):305-8. PubMed ID: 11783113
[TBL] [Abstract][Full Text] [Related]
10. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
11. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro.
Shellard SA; Hosking LK; Hill BT
Cancer Res; 1991 Sep; 51(17):4557-64. PubMed ID: 1873800
[TBL] [Abstract][Full Text] [Related]
12. Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors.
Cullen KJ; Newkirk KA; Schumaker LM; Aldosari N; Rone JD; Haddad BR
Cancer Res; 2003 Dec; 63(23):8097-102. PubMed ID: 14678959
[TBL] [Abstract][Full Text] [Related]
13. Lipoic acid decreases Mcl-1, Bcl-xL and up regulates Bim on ovarian carcinoma cells leading to cell death.
Kafara P; Icard P; Guillamin M; Schwartz L; Lincet H
J Ovarian Res; 2015 Jun; 8():36. PubMed ID: 26063499
[TBL] [Abstract][Full Text] [Related]
14. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.
Lau DH; Lewis AD; Ehsan MN; Sikic BI
Cancer Res; 1991 Oct; 51(19):5181-7. PubMed ID: 1717140
[TBL] [Abstract][Full Text] [Related]
15. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.
Mistry P; Kelland LR; Abel G; Sidhar S; Harrap KR
Br J Cancer; 1991 Aug; 64(2):215-20. PubMed ID: 1892748
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of a glutathione S-transferase pi-activated prodrug in platinum-resistant ovarian cancer cells.
Townsend DM; Shen H; Staros AL; Gaté L; Tew KD
Mol Cancer Ther; 2002 Oct; 1(12):1089-95. PubMed ID: 12481432
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of tumor cell associated Vacuolar-ATPase 'a2' isoform overcomes cisplatin resistance in ovarian cancer cells.
Kulshrestha A; Katara GK; Ginter J; Pamarthy S; Ibrahim SA; Jaiswal MK; Sandulescu C; Periakaruppan R; Dolan J; Gilman-Sachs A; Beaman KD
Mol Oncol; 2016 Jun; 10(6):789-805. PubMed ID: 26899534
[TBL] [Abstract][Full Text] [Related]
18. Glutathione S‑transferase isozyme alpha 1 is predominantly involved in the cisplatin resistance of common types of solid cancer.
Zou M; Hu X; Xu B; Tong T; Jing Y; Xi L; Zhou W; Lu J; Wang X; Yang X; Liao F
Oncol Rep; 2019 Feb; 41(2):989-998. PubMed ID: 30431119
[TBL] [Abstract][Full Text] [Related]
19. Autophagic flux promotes cisplatin resistance in human ovarian carcinoma cells through ATP-mediated lysosomal function.
Ma L; Xu Y; Su J; Yu H; Kang J; Li H; Li X; Xie Q; Yu C; Sun L; Li Y
Int J Oncol; 2015 Nov; 47(5):1890-900. PubMed ID: 26397057
[TBL] [Abstract][Full Text] [Related]
20. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
O'Neill CF; Hunakova L; Kelland LR
Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
